The development of a protective vaccine remains a top priority for the control of the HIV/AIDS
pandemic. Here, we show that a messenger RNA (mRNA) vaccine co-expressing …

Despite the enormous effort in the development of effective vaccines against HIV-1, no
vaccine candidate has elicited broadly neutralizing antibodies in humans. Thus, generation …

Broadly neutralizing antibodies (bNAbs) against HIV-1 develop after prolonged virus and
antibody coevolution. Previous studies showed that sequential immunization with a V3 …

Most existing viral vaccines generate antibodies that either block initial infection or help
eradicate the virus before it can cause disease. For HIV-1, obstacles to eliciting protective …

In 2015, 17 million HIV-infected individuals worldwide were on antiretroviral drug therapies,
which are remarkably effective in suppressing the virus. Yet, 6000 people a day became …

A successful HIV-1 vaccine will require induction of a polyclonal neutralizing antibody (nAb)
response, yet vaccine-mediated induction of such a response in primates remains a …

Recent efforts toward an HIV vaccine focus on inducing broadly neutralizing antibodies, but
eliciting both neutralizing antibodies (nAbs) and cellular responses may be superior. Here …

A goal for an HIV-1 vaccine is to overcome virus variability by inducing broadly neutralizing
antibodies (bnAbs). One key target of bnAbs is the glycan-polypeptide at the base of the …

Virus–specific antibodies protect individuals against a wide variety of viral infections 1–7. To
assess whether human immunodeficiency virus type 1 (HIV–1) envelope–specific antibodies …

The global diversity of HIV-1 represents a critical challenge facing HIV-1 vaccine
development. HIV-1 mosaic antigens are bioinformatically optimized immunogens designed …